.jpg){kind=logo}
| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
PLATELETPHERESIS (LEUKOREDUCED & IRRADIATED)
Test CodePHPLTLI
Physician Attestation of Informed Consent
Yes
Patient Preparation
The patient must have a red wristband for checking against component container label prior to administration. I.V. must be running and consent form must be signed.
Many of the important clinical manifestations of transfusion reaction occur during the administration of the first 50-100mL of blood; therefore, the need for close monitoring is during the early period of transfusion. Temperature, pulse, and blood pressure must be checked and recorded before transfusion and then at 15 minutes after the transfusion is started. Continue to monitor every hour during transfusion.
Minimum Volume
NA
Other Acceptable Specimens
NA
Specimen Stability
Room temperature
Methodology
Irradiation of blood leads to nonviability of donor lymphocytes. 1500 rads is often the dose used.
Setup Schedule
Daily, 24 hours
Clinical Significance
Use:
Avoid graft-vs-host disease in immunodeficient recipients. Blood and cellular components from first-degree relatives must be irradiated.
Additional Information:
Irradiation is not harmful to platelets. Graft-vs-host disease (GVHD) occurs when viable lymphocytes are transfused into severely immunosuppressed patients. The patient is unable to destroy these incoming lymphocytes and they attack the host cells, recognizing them as foreign. GVHD also occurs after allogeneic bone marrow transplantation. Irradiation of blood products prevents GVHD by rendering lymphocytes no longer viable. It has no effect on platelets. Currently, there is no means to prevent GVHD following bone marrow transplantation.
Avoid graft-vs-host disease in immunodeficient recipients. Blood and cellular components from first-degree relatives must be irradiated.
Additional Information:
Irradiation is not harmful to platelets. Graft-vs-host disease (GVHD) occurs when viable lymphocytes are transfused into severely immunosuppressed patients. The patient is unable to destroy these incoming lymphocytes and they attack the host cells, recognizing them as foreign. GVHD also occurs after allogeneic bone marrow transplantation. Irradiation of blood products prevents GVHD by rendering lymphocytes no longer viable. It has no effect on platelets. Currently, there is no means to prevent GVHD following bone marrow transplantation.
Performing Laboratory
Mount Sinai Hospital
Holy Cross Hospital
